Partial
Partially Aligned
Patient Risk:
Low
Summary
The response correctly recognizes several claims supported by the supplied Fluid and Electrolyte Disturbances section, but it also relies on other label sections that were not provided. Those additional label assertions cannot be verified against the supplied prescribing information.
Category Scores
Accurate Statements
The supplied section lists fluid retention, sodium retention, potassium loss, hypokalemic alkalosis, hypertension, and congestive heart failure in susceptible patients.
These items are explicitly listed in the supplied Fluid and Electrolyte Disturbances section.
The supplied section does not specify affected body areas, onset, resolution, or whether weight gain is partly due to fluid.
None of these details appears in the provided section.
Unsupported Statements
FDA labeling describes corticosteroids' anti-inflammatory effects and adrenal suppression.
The supplied label excerpt does not include those statements or the referenced Clinical Pharmacology and Warnings sections.
Labeling states that many corticosteroid adverse effects depend on dose and duration.
This statement is not present in the supplied section, so it cannot support the proposed correction here.
FDA labeling describes effects on glucose tolerance and increased requirements for insulin or oral hypoglycemic agents in people with diabetes.
The supplied section does not address blood glucose or diabetes treatment.
Contradictions
Important Omissions
The response should clearly limit its conclusions to the provided section, rather than treating references to other label sections as verified evidence.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is evaluating label classifications rather than giving direct dosing or treatment instructions. Its main issue is reliance on label content not supplied for this evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several corrections rely on label sections that were not included in the supplied prescribing information.
Suggested Improvement
Restrict conclusions to the provided Fluid and Electrolyte Disturbances section, or identify the other label sections as unavailable and leave those claims unverified.